|
|
Post by kc on Jan 27, 2016 12:22:18 GMT -5
Al invested to bring a great product to market that would held diabetics and to make Money. He is a capitalist businessman. It was about having a winning blockbuster drug. The money for his foundations is there after Al is gone. So first and foremost its MAKING MONEY.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2016 12:23:49 GMT -5
Al invested to bring a great product to market that would held diabetics and to make Money. He is a capitalist businessman. It was about having a winning blockbuster drug. The money for his foundations is there after Al is gone. So first and foremost its MAKING MONEY. and in a right way that would benefit others too unlike other entities like shrekili writing letters to fda to make money.. |
|
|
|
Post by mnholdem on Jan 27, 2016 12:28:19 GMT -5
Here is the exact quote from Al Mann that I was referring to:
While such technology provided the best clinical results in diabetes, I learned that the pharmacokinetics of the prandial insulin products delivered by the pumps were certainly not physiologic. The long persistence of existing insulins causes much of the hypoglycemia in diabetes therapy. I realized that the problem was that those insulins are formulated into six molecule hexamers to stabilize them, and that to utilize the insulin the body takes time to break down the hexamer into monomers. I became very interested in trying to find a way to improve the kinetics of prandial insulins.
We had been exploring ways to stabilize other large molecule drugs for pump delivery and discovered a viable technology that could greatly improve stabilization. I wondered if that technology could stabilize insulin monomers, so I directed creation of such a formulation that turned out to be very successful. When I saw the pharmacokinetics, I said, “My God, that will revolutionize diabetes!” That was before I later realized the magnitude of the challenges bringing a drug product to market, to develop what is now called Afrezza. MannKind has invested about 1.8 billion dollars, of which about 975 million dollars came from me personally. Although that development and regulatory process proved to be a huge challenge, Afrezza is now FDA-approved and we are excited to bring it to market.
|
|
|
|
Post by stevil on Jan 27, 2016 12:34:11 GMT -5
Here is the exact quote from Al Mann that I was referring to:
While such technology provided the best clinical results in diabetes, I learned that the pharmacokinetics of the prandial insulin products delivered by the pumps were certainly not physiologic. The long persistence of existing insulins causes much of the hypoglycemia in diabetes therapy. I realized that the problem was that those insulins are formulated into six molecule hexamers to stabilize them, and that to utilize the insulin the body takes time to break down the hexamer into monomers. I became very interested in trying to find a way to improve the kinetics of prandial insulins.
We had been exploring ways to stabilize other large molecule drugs for pump delivery and discovered a viable technology that could greatly improve stabilization. I wondered if that technology could stabilize insulin monomers, so I directed creation of such a formulation that turned out to be very successful. When I saw the pharmacokinetics, I said, “My God, that will revolutionize diabetes!” That was before I later realized the magnitude of the challenges bringing a drug product to market, to develop what is now called Afrezza. MannKind has invested about 1.8 billion dollars, of which about 975 million dollars came from me personally. Although that development and regulatory process proved to be a huge challenge, Afrezza is now FDA-approved and we are excited to bring it to market.
"My God, that will revolutionize diabetes!" not "My God, that will make a boatload of money!" Sorry, I had to  I promise I'm done now... If someone wants to keep arguing, go ahead and PM me. Let's give our moderators a break. They have to read all of our nonsense. |
|
|
|
Post by compound26 on Jan 27, 2016 13:26:49 GMT -5
I believe Al personally invested about $1 billion into Mannkind (and 10+ years of his life and hard word). He would expect to at least recover his investment. Since Al now owes 40% of Mannkind, I would expect Al to be willing to consider offers of $2.5 billion (and above) for the whole company (around $5/6 per share, considering the current shares outstanding and the existing loans). Admittedly, Mannkind is not in a great position financially, but there are certainly options for Al and Mannkind to get the funds to sustain the operation till the end of 2017. Therefore, if there are no reasonably acceptable offers as described above, I would think Mannkind still could opt to pursue the marketing strategy Matt outlined in the JPM presentation. The value and potential of Afrezza is clearly there. The current PPS of Mannkind is severely depressed by short selling and manipulation. Without these forces, the PPS may well have been around $3-6 right now and that would have enabled Mannkind to pretty easily raise enough money to support Afrezza marketing via a second offering. I think all the potential acquirers (along with Al and Mannkind management) understand this. So a buy-out at $5-6 or higher actually is not that far-fetched. |
|
|
|
Post by beardawg on Jan 28, 2016 8:46:33 GMT -5
Here is the exact quote from Al Mann that I was referring to:
While such technology provided the best clinical results in diabetes, I learned that the pharmacokinetics of the prandial insulin products delivered by the pumps were certainly not physiologic. The long persistence of existing insulins causes much of the hypoglycemia in diabetes therapy. I realized that the problem was that those insulins are formulated into six molecule hexamers to stabilize them, and that to utilize the insulin the body takes time to break down the hexamer into monomers. I became very interested in trying to find a way to improve the kinetics of prandial insulins.
We had been exploring ways to stabilize other large molecule drugs for pump delivery and discovered a viable technology that could greatly improve stabilization. I wondered if that technology could stabilize insulin monomers, so I directed creation of such a formulation that turned out to be very successful. When I saw the pharmacokinetics, I said, “My God, that will revolutionize diabetes!” That was before I later realized the magnitude of the challenges bringing a drug product to market, to develop what is now called Afrezza. MannKind has invested about 1.8 billion dollars, of which about 975 million dollars came from me personally. Although that development and regulatory process proved to be a huge challenge, Afrezza is now FDA-approved and we are excited to bring it to market.
"My God, that will revolutionize diabetes!" not "My God, that will make a boatload of money!" Sorry, I had to I promise I'm done now... If someone wants to keep arguing, go ahead and PM me. Let's give our moderators a break. They have to read all of our nonsense. That's cheap. Get the last word then say "alright, that's enough on the subject, talk privately to me now" so you can't be refuted where everyone would see. That's like me saying on the board, "stevil is a liar/murderer", and giving reasons, then telling you "if you want to discuss this, PM me..." |
|
I promise I'm done now... If someone wants to keep arguing, go ahead and PM me. Let's give our moderators a break. They have to read all of our nonsense. 
